[1]
Blauvelt, A. , Thaci, D., Papp, K., Ho, V. , Ghoreschi, K., Kim, B.S., Miller, M. , Shen, Y.-K. , You, Y., Yu, J., Yang, Y.-W., Crowley, J. and Foley, P. 2022. Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 . SKIN The Journal of Cutaneous Medicine. 6, 2 (Mar. 2022), s2. DOI:https://doi.org/10.25251/skin.6.supp.2.